MCC1 TCR / Fred Hutchinson Cancer Research Center, 2seventy bio  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MCC1 TCR / Fred Hutchinson Cancer Research Center, 2seventy bio
ATTAC-MCC, NCT03747484: Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

Recruiting
1/2
16
US
Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR, Autologous CD8+ and CD4+ T-cells transduced with TCR A2-MCC1, FH-MCVA2TCR, , FH-MCVA2TCR Autologous CD8+ and CD4+ T-cells Transduced with TCR A2-MCC1, Avelumab, 1537032-82-8, Bavencio, Immunoglobulin G1-lambda1, Anti-(Homo sapiens CD274 (Programmed Death Ligand 1, PDL1, pd-l1, B7 Homolog 1, B7H1)), Homo sapiens Monoclonal Antibody, MSB-0010718C, MSB0010718C, Pembrolizumab, Anti-(Human Programmed Cell Death 1), Keytruda, Lambrolizumab, MK-3475, SCH 900475, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, irradiated, Irradiation, NOS, Radiotherapeutics, RADIOTHERAPY, RT
Fred Hutchinson Cancer Research Center, National Cancer Institute (NCI), bluebird bio
Other Skin
10/23
10/23

Download Options